Biohaven secures up to $500 million via term loan financing facility

By Devika Patel

Knoxville, Tenn., Aug. 7 – Biohaven Pharmaceutical Holding Co. Ltd. entered into a $500 million non-dilutive term loan financing facility with Sixth Street, according to a press release.

Up to $375 million will be available immediately upon closing. An additional $125 million will be available if net sales of Nurtec ODT reach $45 million during the first quarter of 2021 or the second quarter of 2021.

Biohaven will use these proceeds for the development, promotion, and commercial launch of Nurtec ODT, as well as for general corporate purposes

The biopharmaceutical company is based in New Haven, Conn.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.